TOXOPLASMOSIS TREATMENT DRUGS MARKET ANALYSIS

Toxoplasmosis Treatment Drugs Market by Drug Class (Pyrimethamine, Spiramycin, Leucovorin, Sulfadiazine, Folic Acid, and Others), by Indication (Chronic Toxoplasmosis Infection and Acute Toxoplasmosis Infection), by Route of Administration (Parenteral and Oral), by Distribution Channel (Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)

Published In : Jul 2023
Code : CMI4166
Pages :250
Formats :
Excel and PDF
Industry : Pharmaceutical

Regional Analysis

Global Toxoplasmosis Treatment Drugs Market- Regional Analysis

Among region, North America is estimated to hold a dominant position in the global toxoplasmosis treatment drugs market over the forecast period owing to increasing research and development of toxoplasmosis treatment. For instance, on March 17, 2022, National Center for Biotechnology Information published a research as both treatment with sulfadiazine and artemether showed significant prolongation in time to death of the infected mice compared to the control group. Median survival days for parenteral artemether, oral artemether, sulfadiazine, and control group were 81,112 and six respectively. Expression of targeted gene in liver and brain of mice after treatment with artemether and sulfadiazine were reduced in comparison to housekeeping gene (β-tubulin gene).

North America: U.S. and Canada
Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
Middle East: GCC, Israel, and Rest of Middle East
Africa: South Africa, North Africa, and Central Africa